| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 08/29/2024 |
3. Issuer Name and Ticker or Trading Symbol
Akoya Biosciences, Inc. [ AKYA ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 82,758 | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Employee Stock Option (Right to Buy) | (1) | 11/12/2031 | Common Stock | 150,000 | 13.34 | D | |
| Employee Stock Option (Right to Buy) | (2) | 02/23/2033 | Common Stock | 25,000 | 12.3 | D | |
| Employee Stock Option (Right to Buy) | (3) | 05/18/2033 | Common Stock | 15,000 | 5.96 | D | |
| Employee Stock Option (Right to Buy) | (4) | 02/22/2034 | Common Stock | 50,000 | 5.35 | D | |
| Explanation of Responses: |
| 1. The option, representing a right to purchase a total of 150,000 shares, became exercisable as follows: one-fourth of the shares vested on September 20, 2022, and the remaining shares vested in 36 equal monthly installments beginning on October 20, 2022. |
| 2. The option, representing a right to purchase a total of 25,000 shares, became exercisable as follows: one-fourth of the shares vested on February 23, 2024 with the remaining shares vesting in 36 equal monthly installments beginning on March 23, 2024, subject to reporting person's continuous employment. |
| 3. The option, representing a right to purchase a total of 15,000 shares, became exercisable as follows: one-fourth of the shares vested on May 18, 2024 with the remaining shares vesting in 36 equal monthly installments beginning on June 18, 2024, subject to reporting person's continuous employment. |
| 4. The option, representing a right to purchase a total of 50,000 shares, becomes exercisable as follows: one-fourth of the shares vests on February 22, 2025 with the remaining shares vesting in 36 equal monthly installments beginning on March 22, 2025, subject to reporting person's continuous employment. |
| /s/ Pascal Bamford by Brian McKelligon, Attorney-in-Fact | 09/03/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
